anti-thymocyte globulin

Generic Name: anti-thymocyte globulin

Clinical Trials

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Acute Leukaemia
Myelodysplasia
Chronic Disease
Leukemia
Lymphoma

Interventions: Drug: Busulfan
Drug: Anti-Thymocyte Globulin
Drug: Fludarabine
Drug: Cyclosporine
Drug: Mycophenolate mofetil

First Posted Date: 2008-11-21

Last Posted Date: 2013-07-30

Lead Sponsor: University of Utah

Target Recruit Count: 47

Registration Number: NCT00795132

Locations: 🇺🇸
Primary Children's Medical Center, Salt Lake City, Utah, United States

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Phase 2

Active, not recruiting

Conditions: Multiple Sclerosis Transplant
Chronic Inflammatory Demyelinating Polyneuropathy
Myasthenia Gravis
Rasmussen Subacute Encephalitis
Neurologic Autoimmune Disease
CIDP Transplant
Central Nervous System Vasculitis
Autoimmune Disease
Autologous Transplant Autoimmune
MS Stem Cell Transplant

Interventions: Biological: Anti-Thymocyte Globulin
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Prednisone
Procedure: Syngeneic Bone Marrow Transplantation

First Posted Date: 2008-07-16

Last Posted Date: 2025-02-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00716066

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Swedish Medical Center-First Hill, Seattle, Washington, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment

Not Applicable

Completed

Conditions: Renal Transplantation
Immunosuppression

Interventions: Drug: anti-thymocyte globulin

First Posted Date: 2008-07-14

Last Posted Date: 2011-08-04

Lead Sponsor: Swedish Medical Center

Target Recruit Count: 3

Registration Number: NCT00714480

Locations: 🇺🇸
Swedish Medical Center, Seattle, Washington, United States

Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients

Not Applicable

Withdrawn

Conditions: Ischemia Reperfusion Injury
Heart Transplantation

Interventions: Drug: Normal Saline
Drug: Anti-Thymocyte Globulin

First Posted Date: 2008-07-03

Last Posted Date: 2013-06-18

Lead Sponsor: University of California, Los Angeles

Registration Number: NCT00709293

Locations: 🇺🇸
Mattel Children's Hospital at UCLA, Los Angeles, California, United States

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

Phase 1

Terminated

Conditions: Type 1 Diabetes Mellitus
Hypoglycemia

Interventions: Biological: Allogeneic islets of Langerhans transplant
Drug: Raptiva
Drug: Sirolimus
Drug: anti-thymocyte globulin

First Posted Date: 2008-05-06

Last Posted Date: 2017-10-25

Lead Sponsor: University of Minnesota

Target Recruit Count: 23

Registration Number: NCT00672204

Locations: 🇺🇸
Universtiy of Minnesota, Minneapolis, Minnesota, United States

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Phase 1

Terminated

Conditions: Stage IV Melanoma
Recurrent Melanoma

First Posted Date: 2007-03-05

Last Posted Date: 2024-03-04

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00003552

Locations: 🇺🇸
National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Phase 1

Completed

Conditions: Breast Cancer
Lymphoma
Leukemia
Myelodysplastic Syndromes
Kidney Cancer
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2006-08-17

Last Posted Date: 2017-11-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 148

Registration Number: NCT00365287

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

Phase 2

Terminated

Conditions: Renal Transplant

Interventions: Drug: Belatacept
Drug: Sirolimus
Drug: Anti-thymocyte globulin
Drug: methylprednisolone

First Posted Date: 2006-06-29

Last Posted Date: 2017-04-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 5

Registration Number: NCT00346151

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

Phase 4

Completed

Conditions: Graft Rejection

Interventions: Drug: Alemtuzumab
Drug: Anti-Thymocyte Globulin

First Posted Date: 2006-05-29

Last Posted Date: 2018-09-06

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 222

Registration Number: NCT00331162

Locations: 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Not Applicable

Terminated

Conditions: Chronic Myeloproliferative Disorders
Diamond-blackfan Anemia
Fanconi Anemia
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2006-02-13

Last Posted Date: 2017-11-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 43

Registration Number: NCT00290628

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy